(ATGE) Adtalem Global Education - Overview
Stock: Healthcare, Nursing, Medicine, Veterinary, Online
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 47.0% |
| Relative Tail Risk | -26.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.11 |
| Alpha | -17.95 |
| Character TTM | |
|---|---|
| Beta | 0.757 |
| Beta Downside | 0.967 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.14% |
| CAGR/Max DD | 0.90 |
Description: ATGE Adtalem Global Education January 10, 2026
Adtalem Global Education Inc. (NYSE: ATGE) operates a portfolio of for-profit institutions that deliver healthcare-focused education across the United States and the Caribbean. Its three operating segments-Chamberlain (nursing and allied health), Walden (online graduate programs), and Medical & Veterinary (medical and veterinary schools)-offer bachelor’s, master’s, doctoral, and certificate programs in fields ranging from nursing and public health to business and criminal justice. The company’s brand lineage traces back to DeVry Education Group, rebranding to Adtalem in May 2017, and it remains headquartered in Chicago, Illinois.
Key quantitative signals as of FY 2023 include revenue of roughly $1.2 billion and a net loss of about $70 million, with total debt near $1.2 billion, yielding a debt-to-EBITDA ratio above 4.0 x-levels that merit close monitoring given the sector’s sensitivity to financing costs. A primary growth driver is the persistent U.S. nursing shortage, projected to require an additional 1 million registered nurses by 2030, which underpins demand for Chamberlain’s programs. Conversely, the for-profit education model faces regulatory headwinds, as state-level oversight and federal student-aid policy changes can materially affect enrollment pipelines and tuition revenue.
For a deeper quantitative view of ATGE’s valuation metrics, the ValueRay platform offers a concise dashboard worth checking.
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income: 253.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 5.49 > 1.0 |
| NWC/Revenue: -7.41% < 20% (prev 1.34%; Δ -8.74% < -1%) |
| CFO/TA 0.16 > 3% & CFO 427.9m > Net Income 253.3m |
| Net Debt (673.3m) to EBITDA (454.1m): 1.48 < 3 |
| Current Ratio: 0.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (36.2m) vs 12m ago -5.65% < -2% |
| Gross Margin: 58.10% > 18% (prev 0.57%; Δ 5753 % > 0.5%) |
| Asset Turnover: 70.77% > 50% (prev 61.98%; Δ 8.79% > 0%) |
| Interest Coverage Ratio: 8.55 > 6 (EBITDA TTM 454.1m / Interest Expense TTM 43.1m) |
Altman Z'' 6.69
| A: -0.05 (Total Current Assets 303.0m - Total Current Liabilities 442.9m) / Total Assets 2.61b |
| B: 1.12 (Retained Earnings 2.92b / Total Assets 2.61b) |
| C: 0.14 (EBIT TTM 368.0m / Avg Total Assets 2.67b) |
| D: 2.36 (Book Value of Equity 2.91b / Total Liabilities 1.24b) |
| Altman-Z'' Score: 6.69 = AAA |
Beneish M -3.02
| DSRI: 0.99 (Receivables 162.8m/147.0m, Revenue 1.89b/1.69b) |
| GMI: 0.98 (GM 58.10% / 56.72%) |
| AQI: 1.03 (AQ_t 0.71 / AQ_t-1 0.69) |
| SGI: 1.12 (Revenue 1.89b / 1.69b) |
| TATA: -0.07 (NI 253.3m - CFO 427.9m) / TA 2.61b) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of ATGE shares?
Over the past week, the price has changed by +0.90%, over one month by -5.47%, over three months by +9.82% and over the past year by -4.30%.
Is ATGE a buy, sell or hold?
- StrongBuy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ATGE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 161.5 | 54.6% |
| Analysts Target Price | 161.5 | 54.6% |
| ValueRay Target Price | 132.8 | 27.1% |
ATGE Fundamental Data Overview February 04, 2026
P/E Forward = 13.9276
P/S = 2.0326
P/B = 2.5917
P/EG = 0.9279
Revenue TTM = 1.89b USD
EBIT TTM = 368.0m USD
EBITDA TTM = 454.1m USD
Long Term Debt = 504.3m USD (from longTermDebt, last quarter)
Short Term Debt = 33.9m USD (from shortTermDebt, last quarter)
Debt = 729.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 673.3m USD (from netDebt column, last quarter)
Enterprise Value = 4.51b USD (3.84b + Debt 729.6m - CCE 56.3m)
Interest Coverage Ratio = 8.55 (Ebit TTM 368.0m / Interest Expense TTM 43.1m)
EV/FCF = 12.26x (Enterprise Value 4.51b / FCF TTM 368.0m)
FCF Yield = 8.16% (FCF TTM 368.0m / Enterprise Value 4.51b)
FCF Margin = 19.48% (FCF TTM 368.0m / Revenue TTM 1.89b)
Net Margin = 13.41% (Net Income TTM 253.3m / Revenue TTM 1.89b)
Gross Margin = 58.10% ((Revenue TTM 1.89b - Cost of Revenue TTM 791.4m) / Revenue TTM)
Gross Margin QoQ = 59.19% (prev 56.57%)
Tobins Q-Ratio = 1.73 (Enterprise Value 4.51b / Total Assets 2.61b)
Interest Expense / Debt = 1.32% (Interest Expense 9.62m / Debt 729.6m)
Taxrate = 25.25% (25.7m / 101.9m)
NOPAT = 275.1m (EBIT 368.0m * (1 - 25.25%))
Current Ratio = 0.68 (Total Current Assets 303.0m / Total Current Liabilities 442.9m)
Debt / Equity = 0.53 (Debt 729.6m / totalStockholderEquity, last quarter 1.38b)
Debt / EBITDA = 1.48 (Net Debt 673.3m / EBITDA 454.1m)
Debt / FCF = 1.83 (Net Debt 673.3m / FCF TTM 368.0m)
Total Stockholder Equity = 1.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.49% (Net Income 253.3m / Total Assets 2.61b)
RoE = 17.76% (Net Income TTM 253.3m / Total Stockholder Equity 1.43b)
RoCE = 19.07% (EBIT 368.0m / Capital Employed (Equity 1.43b + L.T.Debt 504.3m))
RoIC = 13.99% (NOPAT 275.1m / Invested Capital 1.97b)
WACC = 7.47% (E(3.84b)/V(4.57b) * Re(8.70%) + D(729.6m)/V(4.57b) * Rd(1.32%) * (1-Tc(0.25)))
Discount Rate = 8.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.75%
[DCF Debug] Terminal Value 83.01% ; FCFF base≈314.3m ; Y1≈387.8m ; Y5≈660.4m
Fair Price DCF = 342.8 (EV 12.50b - Net Debt 673.3m = Equity 11.83b / Shares 34.5m; r=7.47% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 85.67 | EPS CAGR: 31.51% | SUE: 2.22 | # QB: 9
Revenue Correlation: 95.55 | Revenue CAGR: 9.01% | SUE: 3.47 | # QB: 9
EPS next Quarter (2026-03-31): EPS=1.80 | Chg30d=-0.250 | Revisions Net=-3 | Analysts=3
EPS current Year (2026-06-30): EPS=7.94 | Chg30d=+0.083 | Revisions Net=+3 | Growth EPS=+19.0% | Growth Revenue=+7.8%
EPS next Year (2027-06-30): EPS=8.99 | Chg30d=+0.065 | Revisions Net=+1 | Growth EPS=+13.3% | Growth Revenue=+6.5%